. . . "LULICONAZOLE"@en . . . "NND-502"@en . "The volume of distribution was not quantified."@en . . "Plasma protein binding of luliconazole is >99%."@en . "In clinical trials, no serious toxicity was reported, only local irritation (mild contact dermatitis and cellulitis) at the site of application was found."@en . "Although luliconazole is administered topically, clinical studies have shown that after the first dose in patients with tina pedis, a maximum plasma concentration of 0.40 \u00B1 0.76 ng/mL (mean \u00B1 SD) occurred in 16.9 \u00B1 9.39 hours (mean \u00B1 SD)."@en . . . . . "The route of elimination of luliconazole has yet to be determined."@en . "The exact mechanism of action for luliconazole's anti-fungal activity is still not known, but luliconazole is thought to inhibit the enzyme lanosterol demethylase. Lanosterol demethylase is needed for the synthesis of ergosterol, which is a major component of the fungus cell membranes. "@en . . "The clearance of luliconazole has yet to be determined."@en . . "Fungi"@en . "approved"@en . . "Luliconazole was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. It is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. Luliconazole is also approved in Japan."@en . . . . "187164-19-8"@en . . . . . "Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis. "@en . "The half life of luliconazole has yet to be determined."@en . . . . . . . . . . . . "# Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H: In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother. 1998 Apr;42(4):967-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9559824 # Uchida K, Nishiyama Y, Yamaguchi H: In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother. 2004 Aug;10(4):216-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15365862 # Lexicomp. # FDA label."@en . "Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H: In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother. 1998 Apr;42(4):967-70."@en . " "@en . . .